The present invention is directed toward a composition comprising: an epoxy compound, a polythiol curing agent, and a second curing agent. Also disclosed are methods of treating a substrate with the composition and substrates formed by such methods.

This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.

Described herein is a feasible, significantly simplified production method that avoids challenging lactonization steps and converts a low molecular weight aliphatic polyester, consisting of hydroxy acids and a comonomer, whose molecular weight has been increased by step-growth polymerization reactions. The molecular weight of the aliphatic polyester, based on comparison of initial and final weight average molecular weights (M.sub.w,1/M.sub.w,2), increased significantly at a rate which permits the use of reactive extrusion to produce high molecular weight aliphatic polyesters in a simple, economically feasible manner.

Described herein is a feasible, significantly simplified production method that avoids challenging lactonization steps and converts a low molecular weight aliphatic polyester, consisting of hydroxy acids and a comonomer, whose molecular weight has been increased by step-growth polymerization reactions. The molecular weight of the aliphatic polyester, based on comparison of initial and final weight average molecular weights (M.sub.w,1/M.sub.w,2), increased significantly at a rate which permits the use of reactive extrusion to produce high molecular weight aliphatic polyesters in a simple, economically feasible manner.

Solution casting a nanostructure. Preparing a template by ablating nanoholes in a substrate using single-femtosecond laser machining. Replicating the nanoholes by applying a solution of a polymer and a solvent into the template. After the solvent has substantially dissipated, removing the replica from the substrate.

Solution casting a nanostructure. Preparing a template by ablating nanoholes in a substrate using single-femtosecond laser machining. Replicating the nanoholes by applying a solution of a polymer and a solvent into the template. After the solvent has substantially dissipated, removing the replica from the substrate.

The present invention provides a pharmaceutical composition comprising: a multi-branched copolymer comprising at least three polyester arms, wherein the polyester is poly(ε-caprolactone-co-lactic acid), attached to a central core which comprises a polyether, and wherein the multi-branched copolymer is substantially insoluble in aqueous solution, further comprising at least one pharmaceutically active ingredient, and a pharmaceutically acceptable organic solvent in an amount of at least 20% (w/w %) of the total composition.

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Biodegradable polymers with advantageous physical and chemical properties are described, as well as methods for making such polymers. In one embodiment, a new chemical synthesis route to technologically important biodegradable poly(3-hydroxybutyrate) (P3HB) with high isotacticity and molecular weight required for a practical use is described. The new route can utilize racemic eight-membered cyclic diolide (rac-DL), meso-DL, or a rac-DL and meso-DL mixture, derived from bio-sourced dimethyl succinate, and enantiomeric (R,R)-DL and (S,S)-DL, optically resolved by metal-based catalysts. With a stereoselective racemic molecular catalyst, the ROP of rac-DL under ambient conditions produces rapidly P3HB with essentially perfect isotacticity ([mm]>99%), high crystallinity and melting temperature (T.sub.m=171° C.), as well as high molecular weight and low dispersity (M.sub.n=1.54×10.sup.5 g/mol, Ð=1.01).

Disclosed herein are novel copolymers of poly(ε-caprolactone) (PCL) and polydopamine (PDA), optionally further comprising a PEG chain, methods for making them as well as their use in pharmaceutical preparations, especially implants or in situ gelling depots, for the treatment of ocular disorders or eye diseases.